Innate Pharma’s Post

G-protein-coupled receptor class 5 member D (GPRC5D) is detected in malignant plasma cells in approximately 90% of patients diagnosed with multiple myeloma (MM). In recent preclinical research, a novel humanized bispecific monoclonal antibody, BsAb5003, which targets CD3 and GPRC5D, was evaluated for its therapeutic impact on MM. BsAb5003 efficacy was associated with GPRC5D expression levels in MM cell lines. In addition, BsAb5003 significantly enhanced cytotoxicity when given in combination with immunomodulatory drugs, suggesting that combination treatment with immunomodulatory drugs could be a highly potent and effective therapeutic approach for a broad population of MM patients. Read more: https://lnkd.in/dzErewhK #multiplemyeloma #oncology

Spatial transcriptomics is revolutionizing cancer research. 🧬 This upcoming webinar details this innovative approach, which allows for the visualization and analysis of the entire transcriptome within its histological context, offering unprecedented insights into biomarker behavior and drug performance in patient-derived tumor tissues. Register now to gain insights into how the Indivumed Services platform enhances drug profiling efforts, get an overview of spatial transcriptomics, and understand its role in informing drug treatment decisions. #Transcriptomics #CancerResearch #Biomarkers

🚀 Breaking the Barrier of KRASG12C Inhibitor Resistance 🚀 KRASG12C inhibitors have transformed cancer therapy, targeting the KRASG12C mutation to inhibit tumor growth. Yet, acquired resistance poses a challenge. We've developed resistance models, including Pretreated PDX, Drug-Induced Resistant PDX, and Gene-Engineered Resistant CDX Models, to address this hurdle. Ask me about how these models can advance your drug development efforts today. #CancerResearch #KRASG12C #DrugResistance #Oncology #CancerTherapy #Biotech

Announcing first-in-patient dose for Insilico's novel, first-in-class QPCTL inhibitor, ISM8207, being co-developed with Fosun Pharma. ◾ About ISM8207: The drug candidate was designed using Insilico's generative AI platform for the treatment of advanced malignant tumors. In preclinical studies, ISM8207 demonstrated a significant synergistic anti-tumor effect as a combination agent against multiple solid tumor and hematologic malignancy models, as well as a favorable in vitro ADME and in vivo PK profile. ◾ About the trial: The open-label, multicenter Phase I clinical trial conducted in China aims to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of ISM8207 in patients with lymphoma and other advanced solid tumors. ◾ What the experts are saying: “Compared to current strategies that interfere with the CD47-SIRPα signaling pathway, ISM8027 potentially provides a better margin of safety," says Insilico co-CEO and Chief Scientific Officer Feng Ren. "It not only can enhance immune recognition and attack against cancer cells, but also potentially enhance the anti-cancer efficacy of various standard-of-care therapies." *Link to full press release in comments #ai #genai #drugdiscovery #biotech #pharma #cancer #qpctl #oncology

🌟 Saturday, March 23, 2024 | 16:30 – 18:00 | TME Therapeutics Session Following the TME Diagnostic Session, join us for the TME Therapeutics Session, forming an integral part of the TME Block within our program. Delve into the realm of Tumor Microenvironment (TME) Therapeutics during this enriching session: 🎙 "Clinical Applications and Perspectives of 3BP-3940" by Richard P. Baum (Curanosticum; ICPO, Germany) --- 🎙 "FAPi-Dimers-Chemistry and Preclinical Evaluation" by Dr. Marcel Martin (TetraKit Technologies, Denmark) --- 🎙 "Assessing the Long-term Impact of FAP Dimer Therapy in Cancer Treatment" by sanjana ballal (AIIMS, New Delhi, India) --- 🎙 "Next Generation 64Cu- and 225Ac-labelled Radioligands for FAP-targeted Therapy" by John Babich (Ratio Therapeutics, USA) --- 🎙 "Novel FAP-targeting Small Molecule Radio-conjugates with High and Prolonged Tumor Uptake" by Jacqueline Mock (Philochem, Switzerland) – Online --- 🎙 "Radiotheranostics with Dual Targeting Probe 68Ga-/18F-/177Lu-FAPI-RGD in Diverse Solid Tumors" by Jingjing Zhang (University of Singapore, Singapore) Experience groundbreaking insights and advancements in TME Therapeutics with leading experts! 💡 Still not registered? Secure your spot now: https://lnkd.in/efsT3cDP #TMETherapeutics #TMEBlock #Theranostics #MedicalResearch #TWC2024 🚀

ICT Researchers including Dr Helen Sheldrake have developed a new integrin antagonist, featuring a cyclobutane ring as the central scaffold, aimed at both cancer and non-cancer applications. This innovative approach led to the identification of effective αvβ3 antagonists, showing promising results in cell-based adhesion and invasion assays. The lead compound demonstrated strong in vitro activity, stability, and was well-tolerated in vivo. This work highlights the potential of functionalized cyclobutanes as metabolically stable core structures, offering a robust method for drug development. https://lnkd.in/gkqyFR2F For more info, check our site https://lnkd.in/diBi-RN #DrugDiscovery #CancerResearch #IntegrinAntagonists #Cyclobutanes

Antibody-drug conjugates (ADCs) are transforming personalized oncology by enabling precise drug delivery to cancer cells, thereby optimizing efficacy and minimizing off-target effects. However, existing in vitro preclinical models fall short in capturing the complexity of tumor heterogeneity, which is crucial for accurately assessing ADCs' potential. We understand the difficulties and limitations so we develop Single-AI Chip, to provide unprecedented resolution at single cell response to study antigen heterogeneity and drug resistance at early preclinical stage of ADC candidate development. It’s time to upgrade your preclinical testing pipeline and select the best candidates for clinical trials!! “Make you testing precise with Provectus Therapeutics.”

𝗡𝗲𝘄 𝗗𝗿𝘂𝗴 𝗳𝗼𝗿 𝗕𝗿𝗮𝗶𝗻 𝗧𝘂𝗺𝗼𝗿 – 𝗙𝗶𝗿𝘀𝘁 𝗧𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁   #Glioblastoma is the most common and malignant form of brain tumor. Now, in an ongoing phase 1 clinical trial, the first patient has received a dosage of a novel drug candidate, derived from an #antibody originating at #HelmholtzMunich.     Prof. Reinhard Zeidler spearheaded the basic research at #HelmholtzMunich and provided scientific oversight throughout the transition to clinical trials.     𝗛𝗼𝘄 𝘁𝗵𝗲 𝗱𝗿𝘂𝗴 𝘄𝗼𝗿𝗸𝘀: A highly specific antibody coupled with a radionuclide provided by ITM Isotope Technologies Munich SE seeks to eradicate residual cancer cells that have proven resistant to conventional therapies, thus offering the potential for complete elimination.     Prof. Reinhard Zeidler says:  ”𝙏𝙝𝙚 𝙥𝙝𝙖𝙨𝙚 𝙄 𝙨𝙩𝙪𝙙𝙮 𝙗𝙪𝙞𝙡𝙙𝙨 𝙤𝙣 𝙥𝙧𝙚𝙫𝙞𝙤𝙪𝙨 𝙥𝙧𝙚𝙘𝙡𝙞𝙣𝙞𝙘𝙖𝙡 𝙙𝙖𝙩𝙖 𝙩𝙝𝙖𝙩 𝙥𝙤𝙞𝙣𝙩 𝙩𝙤 𝙧𝙖𝙙𝙞𝙤𝙥𝙝𝙖𝙧𝙢𝙖𝙘𝙚𝙪𝙩𝙞𝙘𝙖𝙡𝙨 𝙖𝙨 𝙖 𝙥𝙤𝙩𝙚𝙣𝙩𝙞𝙖𝙡 𝙣𝙚𝙬 𝙢𝙚𝙩𝙝𝙤𝙙 𝙬𝙞𝙩𝙝 𝙬𝙝𝙞𝙘𝙝 𝙩𝙤 𝙘𝙞𝙧𝙘𝙪𝙢𝙫𝙚𝙣𝙩 𝙥𝙧𝙚𝙫𝙞𝙤𝙪𝙨 𝙘𝙝𝙖𝙡𝙡𝙚𝙣𝙜𝙚𝙨 𝙥𝙤𝙨𝙚𝙙 𝙗𝙮 𝙜𝙡𝙞𝙤𝙗𝙡𝙖𝙨𝙩𝙤𝙢𝙖. 𝙏𝙝𝙞𝙨 𝙣𝙤𝙫𝙚𝙡 𝙙𝙧𝙪𝙜 𝙘𝙖𝙣𝙙𝙞𝙙𝙖𝙩𝙚 𝙞𝙨 𝙪𝙣𝙞𝙦𝙪𝙚 𝙞𝙣 𝙞𝙩𝙨 𝙖𝙗𝙞𝙡𝙞𝙩𝙮 𝙩𝙤 𝙨𝙥𝙧𝙚𝙖𝙙 𝙩𝙝𝙧𝙤𝙪𝙜𝙝𝙤𝙪𝙩 𝙩𝙞𝙨𝙨𝙪𝙚 𝙚𝙖𝙨𝙞𝙡𝙮 – 𝙖 𝙥𝙝𝙖𝙧𝙢𝙖𝙘𝙚𝙪𝙩𝙞𝙘𝙖𝙡 𝙥𝙧𝙤𝙥𝙚𝙧𝙩𝙮 𝙩𝙝𝙖𝙩 𝙝𝙖𝙨 𝙩𝙝𝙚 𝙥𝙤𝙩𝙚𝙣𝙩𝙞𝙖𝙡 𝙩𝙤 𝙢𝙖𝙠𝙚 𝙖 𝙩𝙧𝙪𝙚 𝙙𝙞𝙛𝙛𝙚𝙧𝙚𝙣𝙘𝙚 𝙞𝙣 𝙩𝙧𝙚𝙖𝙩𝙢𝙚𝙣𝙩𝙨 𝙖𝙣𝙙 𝙤𝙪𝙩𝙘𝙤𝙢𝙚𝙨 𝙛𝙤𝙧 𝙥𝙖𝙩𝙞𝙚𝙣𝙩𝙨 𝙘𝙤𝙣𝙛𝙧𝙤𝙣𝙩𝙚𝙙 𝙬𝙞𝙩𝙝 𝙖 𝙗𝙧𝙖𝙞𝙣 𝙘𝙖𝙣𝙘𝙚𝙧 𝙙𝙞𝙖𝙜𝙣𝙤𝙨𝙞𝙨.”  👉 Learn more about how Translational Research at Helmholtz Munich enables the development of game-changing drugs and treatments for a better health:  https://lnkd.in/e2KKEP6A     👉 Learn more about the status of the clinical trial in our news: https://lnkd.in/d6HBcK9v #Glioblastoma #CancerResearch #BrainTumor #ClinicalStudy #brain #tumor #cancer #research #ClinicalTrials

#AntiBodyConjugates (#ADC) trials by phase and #Tumor type